甲磺酸去铁胺 T1637

Product Introduction
Bioactivity


英文名: Deferoxamine Mesylate

描述: Deferoxamine Mesylate (DFOM) 是一种铁螯合剂和铁死亡抑制剂。Deferoxamine Mesylate 可将游离铁结合成稳定的复合物，减少铁的积累。Deferoxamine Mesylate 可以上调 HIF-1α 水平，诱导细胞凋亡。

细胞实验: After cells were seeded onto the collagen-GAG discs and allowed to adhere for 3?hours, they were placed into a hypoxic incubator with 1% O2 or incubated under standard cell culture conditions with deferoxamine mesylate (DFO) added to final concentrations of 30, 60, or 120?μM. Scaffolds seeded with AdMSCs cultured under standard conditions were used as a control [3].

动物实验: The animals were divided into 4 groups: sham, SAH, SAH+vehicle and SAH+DFX (100mg/kg) group. DFX was administered intraperitoneally 2 and 6 hours after hemorrhage followed by every 12 hours for a maximum of 7 days. The same time course and dosage of saline were administered in the SAH+vehicle group. Afterward, rats underwent behavioral testing and were euthanized at day 1, 3, 7 and 28 for brain water content calculation, immunohistochemistry or western blot assays. The study was performed in three parts. Part 1 measured the brain water content, Evan's blue extravasation, and ultrastructural abnormalities at day 1, 3 and 7 after SAH to evaluate the time-dependent changes in brain edema and BBB disruption (n = 4 per time point and group). Part 2 investigated the role of iron in SAH-induced BBB disruption at day 1, 3 and 7 by brain water content (n = 4, per time point and group), Evan's blue extravasation (n = 4, per time point and group), transmission electron microscopy (n = 4, per time point and group), immunohistochemistry (n = 4, per time point and group) and western blot analysis (n = 3, per time point and group). Part 3 compared the acute (n = 61, per group at day 1; n = 42, per group at day 3; n = 23, per group at day 7) and long term (n = 4, per group at day 28) neurological function after SAH in each group to determine the effect of iron chelation on SAH-induced neurologic impairment [4].

体外活性: 方法：人宫颈癌细胞 HeLa 用 Deferoxamine Mesylate (3-100 μM) 处理 72 h，使用 Incucyte HD imaging system 检测细胞数目。结果：Deferoxamine Mesylate 以浓度依赖的方式抑制细胞生长，在100 μM 下观察到显著的生长抑制。[1]方法：人结直肠癌细胞 HT29 和 HCT116 用 Deferoxamine Mesylate (50-200 μM) 处理 48 h，使用 Western Blot 方法检测靶点蛋白表达水平。结果：Deferoxamine Mesylate 以剂量依赖性方式诱导 HIF-1α 的显著表达。[2]方法：人乳腺癌细胞 MDA-MB-231 和 MCF-7 用 Deferoxamine Mesylate (200 μM) 处理 24 h，使用 Flow Cytometry 方法检测细胞凋亡情况。结果：Deferoxamine Mesylate 处理后，与未处理的细胞相比，MDA-MB-231 细胞的凋亡率没有变化，而 MCF-7 细胞的凋亡显著增加。[3]

体内活性: 方法：为研究 Deferoxamine Mesylate 是否能减轻实验小鼠的炎症和动脉粥样硬化，将 Deferoxamine Mesylate (100 mg/kg) 腹腔注射给载脂蛋白 E 缺陷 (apoE-/-) 小鼠，每天一次，持续十周。结果：Deferoxamine Mesylate 使主动脉动脉粥样硬化病变的发展减少 26%。Deferoxamine Mesylate 还降低了血清 MCP-1 水平以及主动脉和心脏中促炎和巨噬细胞标志物的基因表达，同时增加了心脏和肝脏中转铁蛋白受体的蛋白质表达。相反，Deferoxamine Mesylate 治疗对血清胆固醇和甘油三酯水平没有影响。[4]方法：为研究 Deferoxamine Mesylate 对 ob/ob 小鼠附睾脂肪组织中脂肪细胞功能障碍的影响，将 Deferoxamine Mesylate (100 mg/kg) 腹腔注射给 ob/ob 小鼠，每天一次，持续十五天。结果：Deferoxamine Mesylate 通过减少活性氧和炎症标志物的分泌，通过增加抗氧化酶、HIF-1α 和 HIF-1α 靶向蛋白的水平，以及通过改变脂肪细胞铁、葡萄糖和脂质相关代谢蛋白，显著改善了脂肪组织生物学的重要参数。同时，Deferoxamine Mesylate 治疗后，肥大的脂肪细胞体积缩小，胰岛素信号通路相关蛋白也被激活。[5]

存储条件: store at low temperature,keep away from direct sunlightPowder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 152.3 mM
H2O : 20.83 mg/mL (31.72 mM)


关键字: HIFs | neovascularization | TAMSCs | diabetes mellitus | Akt | Deferoxamine Mesylate | PKB | Protein kinase B | Apoptosis | Autophagy | SH-SY5Y | Hypoxia-inducible factors | Deferoxamine | Desferrioxamine B Mesylate | Inhibitor | MEFs | cancer | Alzheimer’s disease | HIF-PH | Reactive Oxygen Species | BMMSCs | inhibit | HIF/HIF Prolyl-Hydroxylase | COVID-19

相关产品: Naringin | Sunitinib | Isoniazid | Doxorubicin hydrochloride | 3-Methyladenine | Valproic Acid | Melatonin | Oxidopamine hydrochloride | Dexamethasone acetate | Metformin

相关库: Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Mitochondria-Targeted Compound Library | Anti-Cancer Drug Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Epigenetics Compound Library | Anti-Cancer Approved Drug Library | Cuproptosis Compound Library | NO PAINS Compound Library

甲磺酸去铁胺 T1637信息由TargetMol中国为您提供，如您想了解更多关于甲磺酸去铁胺 T1637报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途